A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions
Open Access
- 30 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 28 (1), 1-8
- https://doi.org/10.1186/s12929-021-00729-3
Abstract
The spread of SARS-CoV-2, the virus that causes Coronavirus Disease 2019 (COVID-19), has been characterized as a worldwide pandemic. Currently, there are few preclinical animal models that suitably represent infection, as the main point of entry to human cells is via human angiotensin-converting enzyme 2 (ACE2) which is not present in typical preclinical mouse strains. Additionally, SARS-CoV-2 is highly virulent and unsafe for use in many research facilities. Here we describe the development of a preclinical animal model using intranasal administration of ACE2 followed by non-infectious SARS-CoV-2 pseudovirus (PsV) challenge. To specifically generate our SARS-CoV-2 PsV, we used a lentivirus system. Following co-transfection with a packaging plasmid containing HIV Gag and Pol, luciferase-expressing lentiviruses, and a plasmid carrying the SARS-CoV-2 spike protein, SARS-CoV-2 PsVs can be isolated and purified. To better understand and maximize the infectivity of SARS-CoV-2 PsV, we generated PsV carrying spike protein variants known to have varying human ACE2 binding properties, including 19 deletion (19del) and 19del + D614G. Our system demonstrated the ability of PsVs to infect the respiratory passage of mice following intranasal hACE2 transduction. Additionally, we demonstrate in vitro and in vivo manipulability of our system using recombinant receptor-binding domain protein to prevent PsV infection. Our PsV system is able to model SARS-CoV-2 infections in a preclinical mouse model and can be used to test interventions or preventative treatments. We believe that this method can be extended to work in various mouse strains or to model infection with different coronaviruses. A simple in vivo system such as our model is crucial for rapidly and effectively responding to the current COVID-19 pandemic in addition to preparing for future potential coronavirus outbreaks.Keywords
Funding Information
- National Cancer Institute (5P50CA098252)
- National Institutes of Health (5F31CA236051)
This publication has 17 references indexed in Scilit:
- The search for a COVID-19 animal modelScience, 2020
- Cell entry mechanisms of SARS-CoV-2Proceedings of the National Academy of Sciences of the United States of America, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2007
- ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway EpitheliaJournal of Virology, 2005
- Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S ProteinJournal of Virology, 2004
- Efficient Intracellular Assembly of Papillomaviral VectorsJournal of Virology, 2004